Despite well-documented improvement in attention deficit hyperactivity disorder (ADHD) in
youths with the available single and combined pharmacologic agents, a number of youths
remain with residual symptomatology causing impairment in multiple domains. Recent work
has suggested a potential cognitive-enhancing role of cholinergic agents in ADHD. We
describe five cases of ADHD youths aged 8-17 years being treated for ADHD with the
acetylcholinesterase inhibitor donepezil (Aricept®), all of whom demonstrated improvement.

Special Section: Laboratory and performance-based measures of childhood disorders. J
Clin Child Psychol 29: 475, 2000. This introduction to this special section is presented by
Paul J. Frick, who discusses the process by which the special section was prepared and the
critical issues that arose as the topics were developed. This issue provides a review of
existing laboratory and performance-based measures of childhood psychopathology by
recognized experts in specific areas. Twelve articles are presented, and they address such …